Sign Up for a Free Account
  • Updated 05.10.2022
  • Released 12.10.1996
  • Expires For CME 05.10.2025

Chemotherapy: neurologic complications

Introduction

Overview

Patients with cancer are living longer due to earlier diagnoses and remarkable improvements in treatments. Unfortunately, neurologic complications from chemotherapy remain a significant cause of morbidity and may play a role in limiting potential treatments. In addition, novel therapies such as small molecule tyrosine kinase inhibitors, immunotherapy, CAR T cell therapy, and various monoclonal antibodies have been associated with neurologic complications. Because treatments for therapy-induced neurotoxicity are limited, awareness of common neurologic complications is important to prevent permanent damage. The authors review common neurologic complications of both conventional chemotherapy and novel anticancer therapies in this article.

Key points

• Neurologic complications from systemic anticancer therapies impact quality of life and remain an important source of dose-limiting toxicity.

• Although neurotoxicities of chemotherapy are widely known, targeted agents and emerging immunotherapies are also associated with unique patterns of neurologic complications.

• Early recognition and prevention may help avoid permanent neurologic damage.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125